As decades of research have shown, Alzheimer's disease (AD) is not a straightforward process. While AD is a neurological disease, characterized by amyloid plaques and tau tangles in the brain, researchers are increasingly taking interdisciplinary approaches to understand its etiology and possible treatments—targeting a wide variety of biological processes and treatment avenues. Additionally, the Academy's Alzheimer's Disease and Dementia Initiative is bringing together leaders in the academic, industry, and non-profit sectors, seeking collaborative answers to the biggest challenges hindering research and development progress in AD.
Peruse the Academy publications and events below, which cover critical areas of exploration in AD research.
Analyzing dysfunction in the synapse, the regions where two nerve cells meet and communicate, may provide important new insights into the onset and progress of this common form of dementia. This eBriefing presents the work of scientists who are characterizing the changes at the synapse and the effects of diet and exercise on synaptic dysfunction in Alzheimer's disease.
In this eBriefing, scientists from academia and industry share their knowledge on pathogenic mechanisms, vascular outcomes in clinical trials, and drug discovery targets for Alzheimer's disease.
Researchers investigating Alzheimer's, Parkinson's, and Huntington's diseases met at the Academy to discuss the effect of metals in neurodegenerative diseases—and to highlight clinical achievements using metal-binding compounds to influence disease progression.
Monday, May 6, 2013 | 8:15 AM–4:00 PM
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.
September 18–20, 2013
Explore innovative models for advancing the translation of novel neurotechnologies (such as neurostimulation, brain-computer interfaces, and neuron replacement therapies) into diagnostic tools and treatments for neurological and psychiatric disease. The conference will feature a breakout session on Alzheimer's disease. Register by August 9 for early-bird discounts.
November 6–7, 2013
Speakers will put forth a plan to prevent and effectively treat Alzheimer's by 2025 by accelerating the R&D pipeline via new models of precompetitive collaboration, innovative models of financing, and more rapid adoption of digital technology. Register by September 20 for early-bird discounts.
About the New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org.